Clinical and genetic determinants of nevirapine plasma trough concentration
نویسندگان
چکیده
منابع مشابه
Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir.
PURPOSE Triple therapy for HCV-1 infection consists in boceprevir or telaprevir, ribavirin and PEG-interferon. Telaprevir is a P-glycoprotein substrate and it is metabolized by CYP3A4/5. No data have been published on intracellular penetration of telaprevir. We determined peripheral blood mononuclear cells (PBMCs) and trough plasma S and R telaprevir isomers concentrations; moreover, we evaluat...
متن کاملGenetic determinants of plasma triglycerides.
Plasma triglyceride (TG) concentration is reemerging as an important cardiovascular disease risk factor. More complete understanding of the genes and variants that modulate plasma TG should enable development of markers for risk prediction, diagnosis, prognosis, and response to therapies and might help specify new directions for therapeutic interventions. Recent genome-wide association studies ...
متن کاملLoading regimen required to rapidly achieve therapeutic trough plasma concentration of teicoplanin and evaluation of clinical features
BACKGROUND A trough concentration of >20 mg/L is considered the optimal dosage of teicoplanin required to ensure early therapeutic effects against methicillin-resistant Staphylococcus aureus (MRSA) infections including those in patients who develop febrile neutropenia after chemotherapy. This study determines appropriate initial doses during the first 2 days of administration and evaluates the ...
متن کاملElevated Vancomycin Trough Concentration: Increased Efficacy and/or Toxicity?
Vancomycin susceptibility of methicillin-resistant Staphylococcus aureus has been changed over time and its average minimum inhibitory concentration increased from 1.5 to 1.75 mg/L. A recently published guideline by the American Society of Health Pharmacist recommended a daily dose of 15-20 mg/kg every 8 to 12 hours of vancomycin to achieve a trough concentration between 15-20 mg/L for treatmen...
متن کاملClinical and biological determinants of sclerostin plasma concentration in hemodialysis patients.
BACKGROUND Sclerostin is a potent inhibitor of bone formation, but the meaning of its serum levels remains undetermined. We evaluated the association between sclerostin levels and clinical or biological data in hemodialyzed patients (HD), notably parathormone (PTH), biomarkers of bone turnover, vascular calcifications and mortality after 2 years. METHODS 164 HD patients were included in this ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: SAGE Open Medicine
سال: 2018
ISSN: 2050-3121,2050-3121
DOI: 10.1177/2050312118780861